| 12.47 -0.76 (-5.74%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 16.27 | 1-year : | 19.01 |
| Resists | First : | 13.93 | Second : | 16.27 |
| Pivot price | 11.91 |
|||
| Supports | First : | 11.86 | Second : | 10.57 |
| MAs | MA(5) : | 12.51 |
MA(20) : | 12.05 |
| MA(100) : | 12.75 |
MA(250) : | 12.38 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 78.1 |
D(3) : | 73.7 |
| RSI | RSI(14): 53.4 |
|||
| 52-week | High : | 18.47 | Low : | 7.94 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NTLA ] has closed below upper band by 29.7%. Bollinger Bands are 18.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.12 - 13.2 | 13.2 - 13.25 |
| Low: | 11.88 - 11.96 | 11.96 - 12.03 |
| Close: | 12.34 - 12.47 | 12.47 - 12.58 |
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Fri, 30 Oct 2026
Intellia Therapeutics, Inc. (NTLA) stock price, news, quote and history - Yahoo Finance UK
Thu, 29 Oct 2026
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran Investor Event and Seven Presentations at ACAAI 2026 - Investing News Network
Fri, 09 Oct 2026
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? - Yahoo Finance
Thu, 06 Aug 2026
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ... - Yahoo Finance
Fri, 03 Jul 2026
Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now? - Yahoo Finance
Tue, 16 Jun 2026
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 140 (M) |
| Held by Insiders | 1.3421e+008 (%) |
| Held by Institutions | 3.8 (%) |
| Shares Short | 43,930 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.144e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 472.2 % |
| Return on Equity (ttm) | -30.2 % |
| Qtrly Rev. Growth | 5.951e+007 % |
| Gross Profit (p.s.) | -25.67 |
| Sales Per Share | -30.81 |
| EBITDA (p.s.) | -1.23789e+008 |
| Qtrly Earnings Growth | -3.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -347 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.41 |
| Price to Cash Flow | 4.31 |
| Dividend | 0 |
| Forward Dividend | 4.511e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|